Skin and Oral Mucosal Pigmentation as an Early Cutaneous Marker of Vincristine-Based Chemotherapy Toxicity

Authors

  • Wozniak M Department of Dermatology, Jagiellonian University, Krakow, Poland Author
  • Walsh C Department of Medical Oncology, University College Dublin, Dublin, Ireland Author
  • Karagiannis S Department of Oral Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece Author

DOI:

https://doi.org/10.5281/zenodo.22644197

Keywords:

vincristine toxicity, chemotherapy-induced hyperpigmentation, oral mucosal pigmentation, melanonychia, serpentine supravenous hyperpigmentation

Abstract

Background: Vincristine is a core component of chemotherapy regimens for acute lymphoblastic leukemia, lymphoma,
rhabdomyosarcoma, and other malignancies, and its dose-limiting toxicity is classically peripheral neuropathy rather than a
dermatologic effect. However, scattered case reports and broader drug-induced pigmentation reviews have repeatedly described
skin, nail, and oral mucosal pigmentary change in patients receiving vincristine-containing regimens. Objective: To synthesize the
published evidence on cutaneous, ungual, and oral mucosal pigmentation associated with vincristine-based chemotherapy and to
evaluate its potential clinical utility as an early, non-invasive marker of treatment effect. Methods: A narrative review was
conducted of case reports, case series, and systematic reviews addressing chemotherapy-induced mucocutaneous pigmentation,
with particular attention to reports arising in vincristine-containing regimens (vincristine-actinomycin,
vincristine-adriamycin-dexamethasone, hyper-CVAD, R-CHOP, and pediatric leukemia consolidation protocols) and comparator
data from other cytotoxic and targeted agents. Findings: Vincristine-containing regimens have been associated with serpentine
supravenous hyperpigmentation, transverse melanonychia and chromonychia, diffuse melanoderma, reticulate truncal
hypermelanosis, and pigmentation of the nail bed and tongue, with onset typically within one to several treatment cycles and
gradual resolution over months after discontinuation. Because vincristine is administered almost exclusively in combination
regimens, single-agent causal attribution is frequently uncertain, and several reports assign greater causal weight to
co-administered alkylating agents or anthracyclines. Comparator literature indicates that antineoplastic agents broadly account
for roughly a third of drug-induced hyperpigmentation cases, and that oral mucosal pigmentation, though less frequently
documented specifically with vincristine, is a recognized, agent-dependent, and readily inspected finding across cytotoxic regimens.
Conclusions: Skin, nail, and oral mucosal pigmentation is a recurrent, generally benign, and clinically accessible cutaneous
accompaniment of vincristine-based chemotherapy that clinicians can incorporate into routine bedside monitoring, while
recognizing that firm attribution to vincristine alone, as distinct from its regimen partners, remains an area requiring further
dedicated case-level documentation.

References

Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN (2020) Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book, 40:485-500, DOI:10.1200/EDBK_289911.

Marcoux D, Anex R, Russo P (2000) Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. Journal of the American Academy of Dermatology, 43(3):540-546, DOI:10.1067/mjd.2000.106239.

Dasanu CA, Vaillant JG, Alexandrescu DT (2006) Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatology Online Journal, 12(6):10, DOI:10.5070/D321m795kv.

Lopes M, Jordão C, Grynszpan R, Sodré C, Ramos-e-Silva M (2013) Chromonychia secondary to chemotherapy. Case Reports in Dermatology, 5(2):163-167, DOI:10.1159/000351874.

Tisack A, Mohammad TF (2024) Drug-Induced Pigmentation: A Review. Drugs, 84(9):1071-1091, DOI:10.1007/s40265-024-02062-z.

Alharithy R, Alotaibi K, Bin Salamah R, Altamimi R, Alqntash N, Alsarhan R, Khosyfan L, Alrowais S (2026) Drug induced hyperpigmentation: systematic review and meta-analysis. Frontiers in Medicine, 13:1674278, DOI:10.3389/fmed.2026.1674278.

Yamamoto J, Fujimura T, Asano Y (2024) Atypical bilateral hyperpigmented macules on the lower legs possibly due to cyclophosphamide. Case Reports in Dermatology, 17(1):14-18, DOI:10.1159/000543124.

Giménez García RM, Carrasco Molina S (2019) Drug-Induced Hyperpigmentation: Review and Case Series. Journal of the American Board of Family Medicine, 32(4):628-638, DOI:10.3122/jabfm.2019.04.180212.

Shan J, Obiakor BC, Cheng J, Francois RA, Dobry AS (2024) Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review. Archives of Dermatological Research, 316(6):215, DOI:10.1007/s00403-024-03057-2.

Radkhah H, Maleki S, Arabzadeh Bahri R (2024) Serpentine Supravenous Hyperpigmentation, a Phenomenon Following the Administration of Chemotherapeutic Agents: A Systematic Review. Health Science Reports, 7(12):e70294, DOI:10.1002/hsr2.70294.

Kumar S, Bhattacharjee R, Kambhampati SB, Narang T, Kanwar AJ, Vinay K (2021) Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group. Indian Journal of Dermatology, Venereology and Leprology, 87(3):386-388, DOI:10.25259/IJDVL_216_20.

Cohen PR (2016) Paclitaxel-associated reticulate hyperpigmentation: report and review of chemotherapy-induced reticulate hyperpigmentation. World Journal of Clinical Cases, 4(12):390-400, DOI:10.12998/wjcc.v4.i12.390.

Parakh A, Gupta A, Dubey AP (2008) Chemotherapy induced nail changes. Indian Journal of Dermatology, 53(4):204, DOI:10.4103/0019-5154.44804.

Yamada M, Iijima Y, Seo M, Hino S, Sano M, Sakagami H, Horie N, Kaneko T (2023) Cancer chemotherapy-associated pigmentation of the oral mucosa. In Vivo, 37(4):1880-1885, DOI:10.21873/invivo.13280.

Tosios KI, Kalogirou EM, Sklavounou A (2018) Drug-associated hyperpigmentation of the oral mucosa: report of four cases. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 125(3):e54-e66, DOI:10.1016/j.oooo.2017.10.006.

Polizzi E, Abati S, Sandri GF, Finotello L (2024) Differential diagnosis of pigmented lesions in the oral mucosa: a clinical based overview and narrative review. Cancers, 16(13):2487, DOI:10.3390/cancers16132487.

Hanafi T, Titou H, Kerrouch H, Frikh R, Hjira N, Boui M (2020) Hyperpigmentation Associated with Anti-Tumor Chemotherapy: A Series of 54 Cases, Demo-Topographic Aspects and Interest of the Dermatological Intervention. International Journal of Cancer and Clinical Research, 7(1):130, DOI:10.23937/2378-3419/1410130.

Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Journal of the American Academy of Dermatology, 71(2):203.e1-203.e12, DOI:10.1016/j.jaad.2014.04.014.

Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Journal of the American Academy of Dermatology, 71(2):217.e1-217.e11, DOI:10.1016/j.jaad.2014.04.013.

Sutaria A, Saini K, Shah B, Brahmbhatt V, Parmar K (2019) Cutaneous adverse drug reactions to targeted chemotherapeutic drugs: A clinico-epidemiological study. Indian Journal of Dermatology, 64(6):471-478, DOI:10.4103/ijd.IJD_491_18.

Downloads

Published

2024-12-16